Acid Labile Subunit ELISA

$923.00
Catalog
22-ALSHU-E01

The Acid Labile Subunit ELISA is for the quantitative determination of acid labile subunit (ALS) in human serum and plasma (EDTA, heparin, citrate).

Research Use Only. Not for Use in Diagnostic Procedures.
Species
Human
Regulatory Status
Research Use Only. Not for Use in Diagnostic Procedures.
Product Distribution
Available Worldwide
Range
0.53-200 ng/mL
Sensitivity
0.53 ng/mL
Sizes
96 Wells
Sample Types
Citrate Plasma, EDTA Plasma, Heparin Plasma, Serum
Inc Time Hour
3
Inc Time Overnight
No
Inc Time See Protocol
No
Sample Size
10
Detection
Colorimetric

The Insulin-like Growth Factors (IGF) – I and II are bound to specific binding proteins in circulation
(IGFBP). Until today seven different proteins have been identified IGFBP-1 to 7. IGF
bioavailability, transport and storage is regulated or facilitated by these binding proteins which are
expressed differentially according physiological and developmental requirements. The most abundant
IGFBP in circulation is IGFBP-3. Together with IGFBP-5 it is able to form the so called ternary complex
with IGF and the acid-labile subunit (ALS). In the circulation nearly all IGF is bound in this ternary
complex and thus not able to cross the endothelial barrier. Only very small amounts of IGF or IGFBP-3
exist outside this complex. The acid-labile subunit is an important part of the IGF-storage
mechanism in circulation. In ALS deficiency or in ALS knock-out mice the concentration of IGF and
IGFBP-3 in the circulation is significantly decreased resulting in impaired growth.

The acid-labile Subunit, is a synthesized as propeptide of 605 amino acids. The signal peptide,
necessary for ALS secretion (AA 1-27) cleaved off enduring the transport process (Swiss-Prot P35858
Version 82). The mature protein consists of 578 amino acids and contains about 20 leucin rich
sequence repeats. Beside the leucin-rich repeats several potential N-linked glycosylation sides have
been described. Miller BS et al. were able to demonstrate that incomplete glycolsylation of IGFs, ALS
and IGFBP-3 results in a decreased serum concentration of these proteins. Oral mannose therapy
resulted in a partial normalization of the glycosylation pattern and went along with improved growth.

Mutations in or the complete knock out of the ALS gene result in IGF / IGFBP-3 deficiency and
therewith in distribution of growth. Beside growth also other endocrine axes may be involved. In
primary ALS deficiency hyperinsulinemia could be observed. Further, the HGH-IGF-IGFBPsystem
seems to be of relevance in coronary disease.

The first ALS immunoassay was described by Baxter RC in 1990 [6]. By this in-house
radioimmunoassay it was shown that ALS is present in high concentrations in serum (50µg/mL) of
healthy humans. But not detectable in other body fluids like amniotic fluid, cerebrospinal fluid or
seminal plasma – in spite of the fact that these body fluids contain high level IGFBP-3.

Acid Labile Subunit ELISA

22-ALSHU-E01

Billing Address

Shipping Address

Resources to advance your discoveries 

Recent posts

8 Questions to Ask Before Choosing an Allergy Testing Platform
8 Questions to Ask Before Choosing an Allergy Testing Platform
1. What percentage of your IgE allergy testing panel consists of molecular allergens rather than allergen extracts? The ALEX2 IgE allergen panel consists of 117 extracts and 183 molecular allergens. This represents the largest panel of molecular allergens on the market, including 50 unique...
View Now
Understanding IgE Allergy Test Results
Understanding IgE Allergy Test Results
Cases of food and environmental allergies have been increasing over the last decade. While conservative estimates suggest IgE-mediated allergy affects 6-8% of children and 2-3% of adults, some estimates are as high as 30%.3, 2 Symptoms can range from mild to severe and include itching, hives,...
View Now
Improving Food Elimination Diets with IgG Testing
Improving Food Elimination Diets with IgG Testing
Food sensitivity or food intolerance involves a non-allergic response to a food or food additive. In a recent on-line survey conducted in the U.S., 24% of adults aged 18 to 79 reported a food intolerance. While a food allergy is typically mediated by IgE antibodies, adverse reactions to food...
View Now

Recent posts

GLP-1 Amide Elisa
Product Data: Active GLP-1 (7-36) amide Chemiluminescence ELISA
ALPCO’s Active GLP-1 (7-36) amide Chemiluminescence ELISA accurately measures the major biologically active circulating form of GLP-1.1,2 This well-characterized assay provides high analytical sensitivity, a short incubation time, and measures active GLP-1 (7-36) amide in fasted and fed samples.
View Now
 Total Proinsulin Chemiluminescence ELISA
Product Data: Total Proinsulin Chemiluminescence ELISA
ALPCO’s Total Proinsulin Chemiluminescence ELISA offers excellent sensitivity and the greatest dynamic range on the market. 
View Now
Rodent Insulin Chemiluminescence ELISA
Product Data: Rodent Insulin Chemiluminescence ELISA
The STELLUX® Rodent Insulin ELISA provides the flexibility to run both mouse and rat samples on the same plate with minimal to no dilution and a short two hour incubation.
View Now

Biomarkers of Energy Homeostasis Brochure

Energy homeostasis is a focus of research into diabetes and obesity. Read about how our assays in this area can assist both academic and industry researchers.

Complement System Solutions for Drug Development and Clinical Research Datasheet

The complement system is essential to innate immunity from a variety of diseases. ALPCO’s full range of complement system immunoassays can drive discovery.

Melatonin Products for Sleep Disorder-Related Research Datasheet

The melatonin hormone affects the circadian rhythm and sleep-wake cycle. Find out about our immunoassays and products that explore melatonin and sleep disorders.